All enrolled clients who acquired not less than just one dose of zosuquidar or placebo throughout induction were monitored for the prevalence of adverse gatherings (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were being connected to the period of extended and major myelosuppression https://keikon776yjt9.mywikiparty.com/user